Michael Evans, PhD

Professor
Associate Professor
View full UCSF Profile

Biography

Michael Evans, PhD, is a Professor in Residence in the UCSF Department of Radiology and Biomedical Imaging. He is a chemical biologist with an interest in biomarker discovery with proteomics, nuclear medicine, theranostics, and molecular imaging. Dr. Evans earned a BA in Chemistry from St. Mary’s College of Maryland and he obtained his PhD in Organic Chemistry from The Scripps Research Institute (CA) under the supervision of Professor Benjamin Cravatt. This was followed by a postdoctoral fellowship in Molecular Imaging from the Memorial Sloan Kettering Cancer Center in New York under the supervision of Professors Charles Sawyers and Jason Lewis. In 2013, Dr. Evans accepted a faculty position at UCSF.

Dr. Evans has published over 80 peer-reviewed articles, 40 meeting abstracts, and is a co-inventor on 13 patents pending or issued. Dr. Evans also is the principle investigator or co-PI on several human trials focused on new strategies for imaging and treating tumors with radiopharmaceuticals. He is a scientific co-founder and previously served on the scientific advisory board of ORIC Pharmaceuticals, Inc. He is a co-founder of Therapaint, Inc, Honeybear Biosciences, and Hap10, Inc. Dr. Evans is a member of the American Chemical Society, the Society of Nuclear Medicine and Molecular Imaging, and the World Molecular Imaging Society. He has been invited nationally and internationally to lecture about his research. Has been recognized with numerous honors, including a Young Investigator Award from the Prostate Cancer Foundation, a Pathway to Independence Award from the National Cancer Institute, a Research Scholar Award from the American Chemical Society, the 2023 Roger Tsien Award for excellence in chemical biology from the World Molecular Imaging Society, and he was a 2020 inductee to the Council of Distinguished Investigators in the Academy of Radiology and Biomedical Imaging Research.

Expertise:
Chemical Biology, Positron emission tomography, Targeted Radioligand Therapy, Organic Chemistry, Cancer Biology,

Education and Training:
• Bachelor of Art: St. Mary’s College, St. Mary’s City, Maryland - Chemistry
• Doctor of Philosophy: The Scripps Research Institute, La Jolla, California - Organic Chemistry
• Postdoctoral Fellowship: Memorial Sloan Kettering Cancer Center, New York - Molecular Imaging

Education

Postdoctoral, 2013 - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
PhD, 2007 - Chemistry, The Scripps Research Institute
BA, 2001 - Chemistry, Saint Mary's College of Maryland

Honors and Awards

Roger Tsien Award, World Molecular Imaging Society, 2023
Translational Science Grant, V Foundation, 2020-2023
Challenge Award, Prostate Cancer Foundation, 2020-2021
Council of Distinguished Investigators, The Academy for Radiology and Biomedical Imaging Research, 2020
Dean's Apple Award for Teaching, UCSF School of Pharmacy, 2020
Pilot Award, The LAM Foundation, 2019-2020
Research Scholar Award, American Cancer Society, 2017-2021
Discovery Award, American Brain Tumor Association, 2017-2018
Brain Tumor SPORE Developmental Research Project, UCSF, 2016-2018
Precision Imaging of Cancer and Therapy Pilot Award, Helen Diller Family Comprehensive Cancer Center, 2016-2017
Team Science Award, UCSF Academic Senate, 2016-2017
Idea Development Award, DOD Prostate Cancer Research Program, 2015-2017
Pilot Award, UCSF Academic Senate, 2014-2015
David H. Koch Young Investigator Award, Prostate Cancer Foundation, 2013-2016
Pathway to Independence Award, National Cancer Institute, 2012-2017
Research Grant, Imaging and Radiation Sciences Brigde Program, MSKCC, 2012-2014
Research Award, Brain Tumor Center of Memorial Sloan Kettering Cancer Center, 2011
Research Award, Imaging and Radiation Sciences Bridge Program, Memorial Sloan Kettering Cancer Center, 2011
R25 Fellowship, National Institutes of Health and Memorial Sloan Kettering Cancer Center, 2007-2010

Publications

Lee K, Lall R, Chopra S, Evans MJ, Maharbiz MM, Seo Y, Anwar M. SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for Personalized Targeted Radionuclide Cancer Therapy. Int J Radiat Oncol Biol Phys. 2023 Dec 19.
R. Lall, M. Evans, Y. Seo, A. Niknejad, M. Anwar. Dosimetry Reconstruction in Radiopharmaceutical Therapy Using a Sparse Network of External ?-Sensors. International Journal of Radiation Oncology • Biology • Physics. 2023 Oct 1; 117(2):s30-s31.
Sorlin AM, López-Álvarez M, Rabbitt SJ, Alanizi AA, Shuere R, Bobba KN, Blecha J, Sakhamuri S, Evans MJ, Bayles KW, Flavell RR, Rosenberg OS, Sriram R, Desmet T, Nidetzky B, Engel J, Ohliger MA, Fraser JS, Wilson DM. Chemoenzymatic Syntheses of Fluorine-18-Labeled Disaccharides from [18F] FDG Yield Potent Sensors of Living Bacteria In Vivo. J Am Chem Soc. 2023 08 16; 145(32):17632-17642.
Klauser PC, Chopra S, Cao L, Bobba KN, Yu B, Seo Y, Chan E, Flavell RR, Evans MJ, Wang L. Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects. ACS Cent Sci. 2023 Jun 28; 9(6):1241-1251.
Sorlin AM, López-Álvarez M, Rabbitt SJ, Alanizi AA, Shuere R, Bobba KN, Blecha J, Sakhamuri S, Evans MJ, Bayles KW, Flavell RR, Rosenberg OS, Sriram R, Desmet T, Nidetzky B, Engel J, Ohliger MA, Fraser JS, Wilson DM. Chemoenzymatic syntheses of fluorine-18-labeled disaccharides from [ 18 F]FDG yield potent sensors of living bacteria in vivo. bioRxiv. 2023 May 20.
Chopra S, Trepka K, Sakhamuri S, Carretero-González A, Zhu J, Egusa E, Zhou J, Leung K, Zhao N, Hooshdaran N, Feng FY, Wells JA, Chou J, Evans MJ. Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer. Clin Cancer Res. 2023 04 03; 29(7):1232-1242.
S. Martin Aubert, M. Richard, D. Kereselidze, M. Evans, B. Kuhnast, E. Porcel, C. Truillet. Preclinical evaluation of theranostic strategy using nanoplatform and transferrin to target hyperactivity of cMYC in the context of non-small cell lung cancer. Nuklearmedizin - NuclearMedicine. 2023 Mar 1; 47(2):51.
Gonciarz RL, Sakhamuri S, Hooshdaran N, Kumar G, Kim H, Evans MJ, Renslo AR. Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy. Eur J Med Chem. 2023 Mar 05; 249:115110.
R. Lall, K. Lee, S. Chopra, A. Niknejad, M. Evans, M. Anwar. Avalanche Photodiode-Based ?-Photon Scintillation Detectors for Personalized Dosimetry in Targeted Radionuclide Therapy. International Journal of Radiation Oncology • Biology • Physics. 2022 Nov 1; 114(3):e530-e531.
K. Lee, R. Lall, S. Chopra, M.M. Maharbiz, M. Evans, M. Anwar. Personalized Lu177 Theranostic Dosimetry Using a Single Beta-Particle In Vivo Microdosimeter. International Journal of Radiation Oncology • Biology • Physics. 2022 Nov 1; 114(3):s125.
Tran VL, Bouleau A, Nozach H, Richard M, Chevaleyre C, Dubois S, Kereselidze D, Kuhnast B, Evans MJ, Specklin S, Truillet C. Impact of Radiolabeling Strategies on the Pharmacokinetics and Distribution of an Anti-PD-L1 PET Ligand. Mol Pharm. 2022 10 03; 19(10):3673-3680.
Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, Aggarwal R, Evans MJ. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clin Cancer Res. 2022 07 15; 28(14):3066-3075.
Agarwal S, Decavel-Bueff E, Wang YH, Qin H, Santos RD, Evans MJ, Sriram R. Defining the Magnetic Resonance Features of Renal Lesions and Their Response to Everolimus in a Transgenic Mouse Model of Tuberous Sclerosis Complex. Front Oncol. 2022; 12:851192.
Jiang H, Muir RK, Gonciarz RL, Olshen AB, Yeh I, Hann BC, Zhao N, Wang YH, Behr SC, Korkola JE, Evans MJ, Collisson EA, Renslo AR. Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors. J Exp Med. 2022 04 04; 219(4).
Martinko AJ, Simonds EF, Prasad S, Ponce A, Bracken CJ, Wei J, Wang YH, Chow TL, Huang Z, Evans MJ, Wells JA, Hill ZB. Switchable assembly and function of antibody complexes in vivo using a small molecule. Proc Natl Acad Sci U S A. 2022 03 01; 119(9).
Lim SA, Zhou J, Martinko AJ, Wang YH, Filippova EV, Steri V, Wang D, Remesh SG, Liu J, Hann B, Kossiakoff AA, Evans MJ, Leung KK, Wells JA. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. J Clin Invest. 2022 02 15; 132(4).
Kim H, Huang Y, Zhao N, Wang YH, Sakhamuri S, Chopra S, Hooshdaran N, Sriram R, Aggarwal R, Evans MJ. In Vivo Profiling with 18F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions. Mol Pharm. 2022 02 07; 19(2):704-709.
Wei J, Oh DY, Evans MJ. Preparation of Radiolabeled Antibodies for Nuclear Medicine Applications in Immuno-Oncology. Methods Mol Biol. 2022; 2393:829-839.
Bouleau A, Nozach H, Dubois S, Kereselidze D, Chevaleyre C, Wang CI, Evans MJ, Lebon V, Maillère B, Truillet C. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats. J Nucl Med. 2022 08; 63(8):1259-1265.
Meher N, Seo K, Wang S, Bidkar AP, Fogarty M, Dhrona S, Huang X, Tang R, Blaha C, Evans MJ, Raleigh DR, Jun YW, VanBrocklin HF, Desai TA, Wilson DM, Ozawa T, Flavell RR. Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen. ACS Appl Mater Interfaces. 2021 Nov 24; 13(46):54739-54752.
Zhao N, Bardine C, Lourenço AL, Wang YH, Huang Y, Cleary SJ, Wilson DM, Oh DY, Fong L, Looney MR, Evans MJ, Craik CS. In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. ACS Cent Sci. 2021 Oct 27; 7(10):1638-1649.
Tran VL, Lux F, Tournier N, Jego B, Maître X, Anisorac M, Comtat C, Jan S, Selmeczi K, Evans MJ, Tillement O, Kuhnast B, Truillet C. Quantitative Tissue Pharmacokinetics and EPR Effect of AGuIX Nanoparticles: A Multimodal Imaging Study in an Orthotopic Glioblastoma Rat Model and Healthy Macaque. Adv Healthc Mater. 2021 08; 10(16):e2100656.
Ivan de Kouchkovsky, Spencer Behr, Li Zhang, Adam Foye, Henry Vanbrocklin, Eric Jay Small, Felix Y Feng, Terence W. Friedlander, Patricia Li, Natalie Frey, Andy Chung, Austin Lui, Aishwarya Subramanian, Tammy J. Rodvelt, Brigid Barlesi, Michael Evans, Rahul Raj Aggarwal. Feasibility study of gallium-68 citrate PET as a bone-tropic imaging biomarker in mCRPC. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):31-31.
Kalita M, Villanueva-Meyer J, Ohkawa Y, Kalyanaraman C, Chen K, Mohamed E, Parker MFL, Jacobson MP, Phillips JJ, Evans MJ, Wilson DM. Synthesis and Screening of α-Xylosides in Human Glioblastoma Cells. Mol Pharm. 2021 01 04; 18(1):451-460.
Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Clin Cancer Res. 2021 03 01; 27(5):1305-1315.
Zhao N, Huang Y, Wang YH, Muir RK, Chen YC, Wei J, Hooshdaran N, Viswanath P, Seo Y, Ruggero D, Renslo AR, Evans MJ. Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies. J Nucl Med. 2021 07 01; 62(7):949-955.
Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Parker MFL, Blecha JE, Drake CR, VanBrocklin HF, Garrido-Ruiz D, Jacobson MP, Aggarwal R, Behr SC, Flavell RR, Wilson DM, Seo Y, Evans MJ. The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (±)-11C-YJH08 PET. J Nucl Med. 2021 05 10; 62(5):723-731.
Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Mol Imaging Biol. 2020 12; 22(6):1553-1561.
Flavell RR, Evans MJ, Villanueva-Meyer JE, Yom SS. Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):242-257.
Moroz A, Wang YH, Sharib JM, Wei J, Zhao N, Huang Y, Chen Z, Martinko AJ, Zhuo J, Lim SA, Zhang LH, Seo Y, Carlin S, Leung KK, Collisson EA, Kirkwood KS, Wells JA, Evans MJ. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clin Cancer Res. 2020 07 15; 26(14):3608-3615.
Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Blecha JE, VanBrocklin HF, Seo Y, Sayeed M, Feldman BJ, Aggarwal R, Behr SC, Shao H, Wilson DM, Villanueva-Meyer JE, Gestwicki JE, Evans MJ. A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chem Biol. 2020 06 19; 15(6):1381-1391.
Kalita M, Parker MFL, Luu JM, Stewart MN, Blecha JE, VanBrocklin HF, Evans MJ, Flavell RR, Rosenberg OS, Ohliger MA, Wilson DM. Arabinofuranose-derived positron-emission tomography radiotracers for detection of pathogenic microorganisms. J Labelled Comp Radiopharm. 2020 05 15; 63(5):231-239.
Seo Y, Khalighi MM, Wangerin KA, Deller TW, Wang YH, Jivan S, Kohi MP, Aggarwal R, Flavell RR, Behr SC, Evans MJ. Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. Mol Imaging Biol. 2020 02; 22(1):208-216.
Wei J, Leung K, Truillet C, Ruggero D, Wells JA, Evans MJ. Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling. Mol Cell Proteomics. 2020 02; 19(2):294-307.
Wang S, Blaha C, Santos R, Huynh T, Hayes TR, Beckford-Vera DR, Blecha JE, Hong AS, Fogarty M, Hope TA, Raleigh DR, Wilson DM, Evans MJ, VanBrocklin HF, Ozawa T, Flavell RR. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy. Mol Pharm. 2019 09 03; 16(9):3831-3841.
Steven C. Pai, Donald M. Simons, Xiaoqing Lu, Wendy Ritacco, Michael Evans, Gillian Kingsbury, Lawrence Fong. Abstract 550: Tumor-conditional anti-CTLA-4 uncouples anti-tumor efficacy from immunotherapy-related toxicity. Cancer Research. 2019 Jul 1; 79(13_Supplement):550-550.
Muir RK, Zhao N, Wei J, Wang YH, Moroz A, Huang Y, Chen YC, Sriram R, Kurhanewicz J, Ruggero D, Renslo AR, Evans MJ. Measuring Dynamic Changes in the Labile Iron Pool in Vivo with a Reactivity-Based Probe for Positron Emission Tomography. ACS Cent Sci. 2019 Apr 24; 5(4):727-736.
Drake CR, Evans MJ, VanBrocklin HF. Enzymatically Catalyzed Radiofluorination of Biomolecules. Methods Mol Biol. 2019; 2033:191-205.
Pai CS, Simons DM, Lu X, Evans M, Wei J, Wang YH, Chen M, Huang J, Park C, Chang A, Wang J, Westmoreland S, Beam C, Banach D, Bowley D, Dong F, Seagal J, Ritacco W, Richardson PL, Mitra S, Lynch G, Bousquet P, Mankovich J, Kingsbury G, Fong L. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J Clin Invest. 2019 01 02; 129(1):349-363.
Behr SC, Villanueva-Meyer JE, Li Y, Wang YH, Wei J, Moroz A, Lee JK, Hsiao JC, Gao KT, Ma W, Cha S, Wilson DM, Seo Y, Nelson SJ, Chang SM, Evans MJ. Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight. 2018 11 02; 3(21).
Moroz A, Lee CY, Wang YH, Hsiao JC, Sevillano N, Truillet C, Craik CS, Fong L, Wang CI, Evans MJ. A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4. Bioconjug Chem. 2018 10 17; 29(10):3476-3482.
Henry KE, Dacek MM, Dilling TR, Caen JD, Fox IL, Evans MJ, Lewis JS. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clin Cancer Res. 2019 01 01; 25(1):166-176.
Lux F, Tran VL, Thomas E, Dufort S, Rossetti F, Martini M, Truillet C, Doussineau T, Bort G, Denat F, Boschetti F, Angelovski G, Detappe A, Crémillieux Y, Mignet N, Doan BT, Larrat B, Meriaux S, Barbier E, Roux S, Fries P, Müller A, Abadjian MC, Anderson C, Canet-Soulas E, Bouziotis P, Barberi-Heyob M, Frochot C, Verry C, Balosso J, Evans M, Sidi-Boumedine J, Janier M, Butterworth K, McMahon S, Prise K, Aloy MT, Ardail D, Rodriguez-Lafrasse C, Porcel E, Lacombe S, Berbeco R, Allouch A, Perfettini JL, Chargari C, Deutsch E, Le Duc G, Tillement O. AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br J Radiol. 2019 Jan; 92(1093):20180365.
Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2045-2054.
Michael J. Evans, Charles Truillet, Davide Ruggero, Jason S. Lewis, Rahul Aggarwal, Spencer C. Behr. Abstract 3694: Measuring oncogene signaling with transferrin-based PET: From bench to bedside. Clinical Research (Excluding Clinical Trials). 2018 Jul 1; 3694-3694.
Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018 05; 1(1):78-82.
Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018 05 02; 10(439).
C. Truillet, N. Sevillano, B. Jego, E. Jaumain, C. Craik, C.I. Wang, M. Evans. PET imaging of tumor PD-L1 expression with 89Zr-labeled anti-PD-L1 antibodies. Nuklearmedizin. 2018 May 1; 42(3):158.
Truillet C, Parker MFL, Huynh LT, Wei J, Jami KM, Wang YH, Shen YS, Sriram R, Wilson DM, Kurhanewicz J, Evans MJ. Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget. 2018 Apr 17; 9(29):20399-20408.
Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G, Blonder J, Weissman JS, Bandyopadhyay S, Evans MJ, Wells JA. Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Elife. 2018 01 23; 7.
Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. Imaging PD-L1 Expression with ImmunoPET. Bioconjug Chem. 2018 01 17; 29(1):96-103.
de Jesus Cortez F, Nguyen P, Truillet C, Tian B, Kuchenbecker KM, Evans MJ, Webb P, Jacobson MP, Fletterick RJ, England PM. Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen. ACS Chem Biol. 2017 12 15; 12(12):2934-2939.
Lue HW, Podolak J, Kolahi K, Cheng L, Rao S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburg KL, Martinez-Acevedo A, Liu JJ, Amling CL, Truillet C, Louie SM, Anderson KE, Evans MJ, O'Donnell VB, Nomura DK, Drake JM, Ritz A, Thomas GV. Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. Genes Dev. 2017 10 15; 31(20):2067-2084.
Henry KE, Dilling TR, Abdel-Atti D, Edwards KJ, Evans MJ, Lewis JS. Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer. J Nucl Med. 2018 01; 59(1):51-57.
Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 09; 15(9):1221-1229.
Crystal S. Conn, Hao G. Nguyen, Yae Kye, John T. Cunningham, Charles Truillet, Michael Evans, Tony L. Huynh, Peter Walters, Davide Ruggero. Abstract A25: Sensing stress in cancer: a novel therapy targeting protein synthesis through the unfolded protein response in prostate cancer development. Translation Control: an Adaptive Response to Oncogenic Cellular Stress. 2017 Mar 15; a25-a25.
Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ. Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience. Mol Imaging. 2017 Jan-Dec; 16:1536012117723256.
Truillet C, Cunningham JT, Parker MFL, Huynh LT, Conn CS, Ruggero D, Lewis JS, Evans MJ. Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin. Clin Cancer Res. 2017 Jun 15; 23(12):3045-3052.
Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans MJ. A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Mol Imaging Biol. 2016 12; 18(6):946-951.
Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017 Jan; 58(1):81-84.
Truillet C, Thomas E, Lux F, Huynh LT, Tillement O, Evans MJ. Synthesis and Characterization of (89)Zr-Labeled Ultrasmall Nanoparticles. Mol Pharm. 2016 07 05; 13(7):2596-601.
Liu W, Truillet C, Flavell RR, Brewer TF, Evans MJ, Wilson DM, Chang CJ. A reactivity-based [18F]FDG probe for in vivo formaldehyde imaging using positron emission tomography. Chem Sci. 2016 Aug 01; 7(8):5503-5507.
Drake CR, Sevillano N, Truillet C, Craik CS, VanBrocklin HF, Evans MJ. Site-Specific Radiofluorination of Biomolecules with 8-[(18)F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chem Biol. 2016 06 17; 11(6):1587-94.
Carroll VN, Truillet C, Shen B, Flavell RR, Shao X, Evans MJ, VanBrocklin HF, Scott PJ, Chin FT, Wilson DM. [(11)C]Ascorbic and [(11)C]dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. Chem Commun (Camb). 2016 Apr 07; 52(27):4888-90.
Liu, W.; Truillet, C.; Flavell, R.R.; Brewer, T.; Evans, M.J.; Wilson, D.M.; Chang, C.. A Reactivity-Based [18F]FDG Probe for In Vivo Formaldehyde Imaging Using Positron Emission Tomography. Chemical Science. 2016; (7):5503-5507.
Carroll, V.N.; Truillet, C.; Shen, B.; Flavell, R.R.; Shao, X.; Evans, M.J.; VanBrocklin, H.F.; Scott, P.H.J.; Chin, F.T.; Wilson, D.M.. 11C-Ascorbic and 11C-dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. Chemical Communications. 2016; 27(52):4888-4890.
Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans MJ. Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Mol Pharm. 2016 Feb 01; 13(2):683-8.
Flavell RR, Truillet C, Regan MK, Ganguly T, Blecha JE, Kurhanewicz J, VanBrocklin HF, Keshari KR, Chang CJ, Evans MJ, Wilson DM. Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjug Chem. 2016 Jan 20; 27(1):170-8.
Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL. Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res. 2015 Nov 15; 75(22):4688-96.
Gerdtsson A, Poon JB, Thorek DL, Mucci LA, Evans MJ, Scardino P, Abrahamsson PA, Nilsson P, Manjer J, Bjartell A, Malm J, Vickers A, Freedland SJ, Lilja H, Ulmert D. Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. Eur Urol. 2015 Dec; 68(6):1076-82.
Doran MG, Watson PA, Cheal SM, Spratt DE, Wongvipat J, Steckler JM, Carrasquillo JA, Evans MJ, Lewis JS. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET. J Nucl Med. 2014 Dec; 55(12):2045-9.
Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ. Cabozantinib Resolves Bone Scans in Tumor-Naïve Mice Harboring Skeletal Injuries. Mol Imaging. 2014 Oct 01; 13(8):7290201400026.
D.E. Spratt, M.G. Doran, J. Wongvipat, J.S. Lewis, M.J. Evans. 89Zr-MSTP2109A, A Novel Antibody Based Radiotracer to Evaluate and Guide the Clinical Translation of Antibody-Drug Conjugates Targeting STEAP1. International Journal of Radiation Oncology • Biology • Physics. 2014 Sep 1; 90(1):s791.
Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014 Aug 15; 28(16):1800-14.
Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, Larson SM. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014 May; 41(5):985-94.
Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ. Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Mol Imaging. 2014; 13.
Zeglis BM, Houghton JL, Evans MJ, Viola-Villegas N, Lewis JS. Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. Inorg Chem. 2014 Feb 17; 53(4):1880-99.
Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak KK, Drobjnak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med. 2013 Nov; 54(11):1876-82.
Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thromb Haemost. 2013 Sep; 110(3):484-92.
Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013 Apr 09; 2:e00499.
Stelter L, Evans MJ, Jungbluth AA, Longo VA, Zanzonico P, Ritter G, Bomalaski JS, Old L, Larson SM. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. Mol Imaging. 2013 Jan-Feb; 12(1):67-73.
Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL, Lewis JS. Imaging tumor burden in the brain with 89Zr-transferrin. J Nucl Med. 2013 Jan; 54(1):90-5.
Evans MJ. Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. Cancer Discov. 2012 Nov; 2(11):985-94.
Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. Annotating MYC status with 89Zr-transferrin imaging. Nat Med. 2012 Oct; 18(10):1586-91.
Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012 Apr; 2(4):320-7.
Steven M. Larson, Joe Fox, Michael Morris, Michael Evans, Jason Lewis, John Humm, Charles L. Sawyers, Howard I. Scher. Abstract IA22: Molecular Imaging of androgen receptor signalling in CRPC. Cancer Research. 2012 Feb 6; 72(4 Supplement):ia22-ia22.
Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, Bjartell A, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, Larson SM. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012 Jul; 62(1):78-84.
Stelter L, Evans MJ, Jungbluth AA, Zanzonico P, Ritter G, Ku T, Rosenfeld E, Bomalaski JS, Old L, Larson SM. Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma. J Nucl Med. 2012 Feb; 53(2):281-6.
Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011 Jun 07; 108(23):9578-82.
Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A. 2010 Apr 06; 107(14):6459-64.
Michael J. Evans, Peter Smith-Jones, John Wongvipat, Steven M. Larson, Charles L. Sawyers. Abstract B207: Prostate specific membrane antigen is a diagnostic marker of response to allosteric androgen receptor inhibition. Molecular Cancer Therapeutics. 2009 Dec 10; 8(12_Supplement):b207-b207.
Evans MJ, Holland GP, Garcia-Garcia FJ, Häussermann U. Polyanionic gallium hydrides from AlB2-type precursors AeGaE (Ae = Ca, Sr, Ba; E = Si, Ge, Sn). J Am Chem Soc. 2008 Sep 10; 130(36):12139-47.
Evans MJ, Morris GM, Wu J, Olson AJ, Sorensen EJ, Cravatt BF. Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides. Mol Biosyst. 2007 Jul; 3(7):495-506.
Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, Patapoutian A. Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007 Feb 01; 445(7127):541-5.
Evans MJ, Cravatt BF. Mechanism-based profiling of enzyme families. Chem Rev. 2006 Aug; 106(8):3279-301.
Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol. 2005 Oct; 23(10):1303-7.